These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 29228881)

  • 21. Lysine acetyltransferase inhibitors: structure-activity relationships and potential therapeutic implications.
    Fiorentino F; Mai A; Rotili D
    Future Med Chem; 2018 May; 10(9):1067-1091. PubMed ID: 29676588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of a PCAF Bromodomain Chemical Probe.
    Moustakim M; Clark PG; Trulli L; Fuentes de Arriba AL; Ehebauer MT; Chaikuad A; Murphy EJ; Mendez-Johnson J; Daniels D; Hou CD; Lin YH; Walker JR; Hui R; Yang H; Dorrell L; Rogers CM; Monteiro OP; Fedorov O; Huber KV; Knapp S; Heer J; Dixon DJ; Brennan PE
    Angew Chem Int Ed Engl; 2017 Jan; 56(3):827-831. PubMed ID: 27966810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. E-pharmacophore-based virtual screening to identify GSK-3β inhibitors.
    Natarajan P; Priyadarshini V; Pradhan D; Manne M; Swargam S; Kanipakam H; Bhuma V; Amineni U
    J Recept Signal Transduct Res; 2016 Oct; 36(5):445-58. PubMed ID: 27305963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protein lysine acetyltransferase CBP/p300: A promising target for small molecules in cancer treatment.
    Gou P; Zhang W
    Biomed Pharmacother; 2024 Feb; 171():116130. PubMed ID: 38215693
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of Pyrrolo[3,2- d]pyrimidin-4-one Derivatives as a New Class of Potent and Cell-Active Inhibitors of P300/CBP-Associated Factor Bromodomain.
    Huang L; Li H; Li L; Niu L; Seupel R; Wu C; Cheng W; Chen C; Ding B; Brennan PE; Yang S
    J Med Chem; 2019 May; 62(9):4526-4542. PubMed ID: 30998845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Theoretical research in structure characteristics of different inhibitors and differences of binding modes with CBP bromodomain.
    Wang XS; Zheng QC
    Bioorg Med Chem; 2018 Feb; 26(3):712-720. PubMed ID: 29329830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of promising FtsZ inhibitors by E-pharmacophore, 3D-QSAR, molecular docking study, and molecular dynamics simulation.
    Qiu Y; Zhou L; Hu Y; Bao Y
    J Recept Signal Transduct Res; 2019 Apr; 39(2):154-166. PubMed ID: 31355691
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of small molecule inhibitors targeting the SMARCA2 bromodomain from a high-throughput screening assay.
    Lu T; Hu JC; Lu WC; Han J; Ding H; Jiang H; Zhang YY; Yue LY; Chen SJ; Jiang HL; Chen KX; Chai HF; Luo C
    Acta Pharmacol Sin; 2018 Sep; 39(9):1544-1552. PubMed ID: 29795359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Virtual screen to NMR (VS2NMR): Discovery of fragment hits for the CBP bromodomain.
    Spiliotopoulos D; Zhu J; Wamhoff EC; Deerain N; Marchand JR; Aretz J; Rademacher C; Caflisch A
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2472-2478. PubMed ID: 28410781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent Advances on Small-Molecule Bromodomain-Containing Histone Acetyltransferase Inhibitors.
    Liu M; Zhang K; Li Q; Pang H; Pan Z; Huang X; Wang L; Wu F; He G
    J Med Chem; 2023 Feb; 66(3):1678-1699. PubMed ID: 36695774
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of a Potent, Cell Penetrant, and Selective p300/CBP-Associated Factor (PCAF)/General Control Nonderepressible 5 (GCN5) Bromodomain Chemical Probe.
    Humphreys PG; Bamborough P; Chung CW; Craggs PD; Gordon L; Grandi P; Hayhow TG; Hussain J; Jones KL; Lindon M; Michon AM; Renaux JF; Suckling CJ; Tough DF; Prinjha RK
    J Med Chem; 2017 Jan; 60(2):695-709. PubMed ID: 28002667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Computer-aided identification of lead compounds as Staphylococcal epidermidis FtsZ inhibitors using molecular docking, virtual screening, DFT analysis, and molecular dynamic simulation.
    Tripathy S; Sahu SK; Azam MA; Jupudi S
    J Mol Model; 2019 Nov; 25(12):360. PubMed ID: 31773394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of Selective CBP/P300 Benzoxazepine Bromodomain Inhibitors.
    Popp TA; Tallant C; Rogers C; Fedorov O; Brennan PE; Müller S; Knapp S; Bracher F
    J Med Chem; 2016 Oct; 59(19):8889-8912. PubMed ID: 27673482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Crystal structure of GCN5 PCAF N-terminal domain reveals atypical ubiquitin ligase structure.
    Toma-Fukai S; Hibi R; Naganuma T; Sakai M; Saijo S; Shimizu N; Matsumoto M; Shimizu T
    J Biol Chem; 2020 Oct; 295(43):14630-14639. PubMed ID: 32820047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Covalent-Fragment Screening of BRD4 Identifies a Ligandable Site Orthogonal to the Acetyl-Lysine Binding Sites.
    Olp MD; Sprague DJ; Goetz CJ; Kathman SG; Wynia-Smith SL; Shishodia S; Summers SB; Xu Z; Statsyuk AV; Smith BC
    ACS Chem Biol; 2020 Apr; 15(4):1036-1049. PubMed ID: 32149490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploration of New and Potent Lead Molecules Against CAAX Prenyl Protease I of Leishmania donovani Through Pharmacophore Based Virtual Screening Approach.
    Prabhu SV; Tiwari K; Suryanarayanan V; Dubey VK; Singh SK
    Comb Chem High Throughput Screen; 2017; 20(3):255-271. PubMed ID: 28116998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ligand- and structure-based in silico studies to identify kinesin spindle protein (KSP) inhibitors as potential anticancer agents.
    Balakumar C; Ramesh M; Tham CL; Khathi SP; Kozielski F; Srinivasulu C; Hampannavar GA; Sayyad N; Soliman ME; Karpoormath R
    J Biomol Struct Dyn; 2018 Nov; 36(14):3687-3704. PubMed ID: 29064326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular docking and dynamics simulation study of flavonoids as BET bromodomain inhibitors.
    Raj U; Kumar H; Varadwaj PK
    J Biomol Struct Dyn; 2017 Aug; 35(11):2351-2362. PubMed ID: 27494802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular dynamics guided insight, binding free energy calculations and pharmacophore-based virtual screening for the identification of potential VEGFR2 inhibitors.
    Rathi E; Kumar A; Kini SG
    J Recept Signal Transduct Res; 2019; 39(5-6):415-433. PubMed ID: 31755336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure-based virtual screening of the nociceptin receptor: hybrid docking and shape-based approaches for improved hit identification.
    Daga PR; Polgar WE; Zaveri NT
    J Chem Inf Model; 2014 Oct; 54(10):2732-43. PubMed ID: 25148595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.